ZYBERNO
Stock Report
Updated Aug 27, 2026

MEDICUS PHARMA LTD. (MDCXW)

Healthcare • NASDAQ

$0.33

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
4.0/100
POOR BUSINESS
MEDICUS PHARMA LTD. (MDCXW) scores 4/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-271.9%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

MEDICUS PHARMA LTD. (MDCXW) stock report — Zyberno Score 4/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.33
Market Cap:$18.23M

Valuation Multiples (1)

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$3.51M

Price Action & Momentum (1)

% of 52-Week High:22.8%
B. Profitability Assessment

Return Metrics (4)

ROA:-497.9%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$727.66
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.57x
Quick Ratio:1.57x
Cash Ratio:1.40x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-54.37x
Times Interest Earned:-54.37

Capital Structure (4)

Working Capital:6,140,096.00
Cash And Cash Equivalents:15,174,128.00
Long Term Debt:$137.33K
Net Debt:-$14.73M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$43.29M

Bottom Line Performance (3)

-$67.94M
Income Before Tax:-$16.82M
Ebitda Ttm:-43,292,806.00

Operating Expenses (5)

Operating Expenses:43,292,806.00
R And D Expense:18,920,435.00
Sga Expense:22,687,588.00
Income Tax Expense:$0.00
Interest Expense:631,926.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$27.12M
Current Assets:$16.98M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:28,841,149.00
Current Liabilities:10,841,493.00
Long Term Debt:$137.33K
Short Term Debt:$308.01K

Equity & Capital (3)

Equity:-$1.72M
Retained Earnings:-$85.01M
Common Stock:74,298,513.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:6,734,310.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:1,405,826.00
C. Cash Flow Analysis

Operating Activities (2)

-$27.81M$0.00

Investment Activities (1)

Investing Cash Flow:-$4.62M

Financing Activities (3)

Financing Cash Flow:$6.83M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$11.87M
Long Term Debt Repayments:$3.18M
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-2.41
-$2.41
Earnings Per Share Ttm:-$1.23

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.41

Book Value & Capital (2)

Book Value Per Share:-$0.03
Cash Per Share:0.28

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-50.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:MDCXW
Company Name:MEDICUS PHARMA LTD.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:55.06M
Shares Outstanding Basic:55.06M
Shares Outstanding Diluted:55.06M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-27 01:12:03 UTC
Data Timestamp:2026-08-27T01:12:03.044072
Scroll to Top